

The Pharma Cartel: America's COVID-19 Vaccine Market Remains Closed Off to Outside Competition

By [Jordan Schachtel](#)

Global Research, January 06, 2022

[The COVID World](#) 5 January 2022

Region: [USA](#)

Theme: [Intelligence](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@globalresearch_crg](#).

Are government regulators minimizing the availability of COVID vaccine options in the United States in order to protect our health, or are there many other factors in play — that are completely unrelated to our health — being considered behind the curtain?

The U.S. COVID-19 vaccine market has been shut out to outside competition for almost a year. Despite these shots being [marketed](#) and sold as akin to a cure to a coronavirus, they have catastrophically failed to achieve that result. Despite **COVID-19** being declared **the pandemic of the century**, American regulatory agencies remain adamantly opposed to opening the market to more participants.

On December 11th, 2020, the FDA issued emergency use authorization (EUA) to **Pfizer and BioNTech** for their COVID-19 vaccine. The U.S. government has since spent billions of taxpayer dollars on hundreds of millions of **Pfizer shots**.

On December 18th, 2020, the FDA issued an EUA to **Moderna** for their COVID-19 vaccine. The U.S. government has since spent billions of taxpayer dollars on hundreds of millions of **Moderna shots**.

On February 27th, 2021, the FDA issued an EUA to **Johnson & Johnson** for their COVID-19 vaccine. The U.S. government has since spent billions of taxpayer dollars on hundreds of millions of **Johnson & Johnson shots**.

All of these shots were developed in **early 2020**. None have been updated or optimized for variants. Yet they remain the only three shots in town.

Since the early 2021 J&J approval, the FDA has failed to **authorize any other candidates for emergency use**. The overwhelming majority of taxpayer funds spent on COVID vaccines have gone to **Moderna and Pfizer**.

Now, some of you readers will know by now that I have become deeply skeptical of the

merits of this **entire new market**, which is rife with the worst of pharmaceutical snake oil salesmen. However, it is worth exploring why the U.S. continues to operate under the **Big Three vaccine paradigm**.

The COVID-19 problem has not exactly gone away, and the global **COVID-19 vaccine market** has ballooned into a massive industry, with hundreds of candidates surfacing from all over the world.

Why does the United States still only have **3 authorized COVID vaccines** (the approved Pfizer shot remains inaccessible in the United States) for emergency use only? Let's take a global snapshot of what's going on elsewhere.

The European Medicines Agency has authorized **5 COVID vaccines for use**. They list the **Big Three U.S. shots plus Novavax and AstraZeneca**. Additionally, European regulators have listed 4 other shots under a "**rolling review**" process.

The World Health Organization (**WHO**) now lists [10 COVID vaccines](#) that are approved for use under their emergency use listing authority.

What are individual nations doing?

America's top competitors are pursuing a "**vaccine nationalism**" strategy. **China** has authorized **6 shots** (4 of which are inactivated vaccines), and all of them are produced by **Chinese companies**.

Russia has authorized **4**, and all of them are produced by **Russian companies**.

Most countries are pursuing their vaccine strategy in line with their current alliance structure. This reality does not seem to conform to the narrative of a global, devastating plague, but rather, a **geopolitical struggle in the name of a virus**. China's allies are committing to **China's vaccines**. Russia's allies are committing to **Russia's vaccines**. The Western world is committing to the U.S.-based shots, plus the **Oxford-Astrazeneca shot**.

Other nations seem to be engaging in a "**we hope something will work**" strategy. Indonesia and the Philippines have authorized **11 shots**. India, Mexico, Hungary, and Argentina have authorized **9 shots**. Vietnam has allowed for **8**. Nigeria and Pakistan have said yes to **7**.

U.S. "public health" officials have defended the cartel behavior of the **Biden Administration**, claiming Americans already have access to the very best **COVID shots**. In late May, the **FDA** reinforced this position by notifying manufacturers that it may start issuing blanket rejections for new **EUA applications**, claiming it is too much of a regulatory hassle to go through all of their new data.



Still, companies from around the world continue to submit **EUA applications** for their **COVID-19 vaccines**, with zero having secured the golden ticket to the **U.S. market**. It remains **mRNA or bust** in the United States.

U.S. public health bureaucrat **Anthony Fauci** was pushed on this issue in an interview at the end of the year. The D.C. lifer rejected the idea that America should open up the playing

field to promising candidates outside of the **mRNA (Moderna and Pfizer) vaccines**.

When the host asked if the U.S. would entertain the merits of **Covaxin** (an inactivated vaccine candidate from India's Bharat Biotech), Fauci went nuclear on her.

"We have enough vaccines, the best vaccines available in the United States ... **We have what we need**. We need to use it.

We don't need another vaccine. **We have plenty of vaccines.**"

<https://thecovidworld.com/wp-content/uploads/2022/01/Fauci.mp4>

Despite America's current regime claiming that Americans have access to the "**very best**" shots in every major pharmacy across our country, the actual **COVID datasure** doesn't suggest anything resembling the idea that our **mRNA dominant approach** is acting in a more beneficial manner than any other candidate available across the world.

It certainly seems to be a no-brainer that the U.S. would be better off allowing more competitors to enter the space. The [hundreds](#) of **Big Pharma lobbyists** who represent the interests of the **Big Three** would prefer that never happens. And once again, in line with the recurring theme throughout **COVID Mania**, it seems that **America's ruling class** is making regulatory decisions far removed from its citizens' actual health interests.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from The COVID World

The original source of this article is [The COVID World](#)
Copyright © [Jordan Schachtel](#), [The COVID World](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Jordan Schachtel](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those

who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca